Collegium Pharmaceutical executed a $50 million accelerated share repurchase agreement with Jefferies, the company disclosed Thursday morning. The program drew immediate pre-market volume, with shares lifting 4.2% before the open. The timing matters: Collegium trades at $31.47, roughly 18% below its 52-week high of $38.42, despite revenue growth in its ADHD stimulant portfolio.
The ASR structure means Collegium receives roughly 80% of the shares upfront, with final settlement tied to volume-weighted average pricing over the program period. Jefferies borrows shares to deliver immediately, then purchases in the open market over subsequent weeks. Collegium's float is 27.3 million shares, so the initial delivery alone removes approximately 3-4% of tradable supply. The company holds $187 million in cash and equivalents as of the most recent quarter, making this deployment 26.7% of liquid assets.
Collegium generates revenue primarily through Jornay PM, an evening-dosed methylphenidate for ADHD, and Xtampza ER, an abuse-deterrent oxycodone. The ADHD market saw prescription volume growth of 5.1% year-over-year in Q3 2024, with Jornay capturing incremental share among pediatric patients. The company reported $111.2 million in Q3 revenue, up 9.8% from the prior year, but gross margins compressed 210 basis points due to channel mix and rebate pressure. Operating cash flow for the trailing twelve months sits at $68 million, meaning this repurchase consumes roughly 73% of annual free cash generation.
The capital allocation choice signals management's view on intrinsic value versus external deployment. Collegium trades at 2.7x trailing revenue and 11.4x forward earnings, below the median 14.2x for specialty pharmaceutical peers with single-product concentration. The company has no meaningful M&A pipeline disclosed, and its pipeline beyond line extensions remains sparse. The ASR effectively bets that buying shares below $32 generates better returns than funding clinical trials or pursuing bolt-on acquisitions in adjacent pain or neurology franchises.
Allocators should watch Q4 earnings in late February for updated ADHD market share data and any revisions to 2025 gross margin guidance. The ASR settlement will likely complete by mid-March, so the final share count and weighted-average price will appear in the Q1 filing. Jefferies' open-market buying creates a technical bid over the next 6-8 weeks, but the real test is whether Jornay continues to take share from Concerta and Adderall XR generics. If prescription trends weaken or rebate pressure accelerates, the repurchase looks less strategic and more defensive.
Collegium's $50 million commitment at current levels prices in confidence that ADHD demand holds and margin pressure stabilizes. Whether the stock is actually cheap depends entirely on whether the company can grow revenue faster than rebate erosion, and the ASR gives management exactly zero room for error on that equation.